Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Details)

v3.24.1.1.u2
Segment reporting (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
USD ($)
segment
Mar. 31, 2023
USD ($)
Segment reporting    
Number of Operating Segments | segment 1  
Revenues $ 5,678 $ 47,601
Total operating expenses (54,939) (45,945)
Operating (loss)/profit (49,261) 1,656
Interest income 1,345 676
Other income (expense), net 61 671
Income tax expense (526) (625)
Segment and consolidated net (loss)/profit 48,503 (1,036)
Research    
Segment reporting    
Total operating expenses (3,800) (3,500)
CMC and Quality    
Segment reporting    
Total operating expenses (14,200) (14,300)
Biomarkers    
Segment reporting    
Total operating expenses (2,500) (1,200)
Development and Compliance    
Segment reporting    
Total operating expenses (12,600) (9,200)
Infrastructure Management and Facilities    
Segment reporting    
Total operating expenses (7,700) (6,200)
Commercial planning    
Segment reporting    
Total operating expenses (2,600) (1,100)
Support functions    
Segment reporting    
Total operating expenses (9,000) (13,600)
Other    
Segment reporting    
Total operating expenses $ (2,539) $ 3,155